Pulse Biosciences Appoints Experienced Medtech Leader Liane Teplitsky as Chief Operating Officer

summarizeSummary

Pulse Biosciences appointed Liane R. Teplitsky, an experienced medtech executive, as Chief Operating Officer, bolstering its leadership for the commercialization of its nPulse Cardiac Catheter System.

check_boxKey Events

• New Chief Operating Officer Appointed

  Liane R. Teplitsky, an executive with two decades of experience in medical technology, including leadership roles at Abbott Laboratories and Zimmer Biomet, was appointed Chief Operating Officer, effective April 8, 2026.

• Strategic Leadership for Commercialization

  Ms. Teplitsky will oversee Clinical, Regulatory, Quality, and Commercial functions, aligning with the company's focus on accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System.

• Performance-Based Equity Compensation

  Ms. Teplitsky received options to purchase 700,000 shares and 200,000 restricted stock units, with a significant portion vesting upon achievement of ambitious market capitalization and product revenue milestones, including targets up to $5 billion market cap and $300 million in revenue.

auto_awesomeAnalysis

The appointment of Liane R. Teplitsky as Chief Operating Officer significantly strengthens Pulse Biosciences' executive team, particularly as the company advances its nPulse Cardiac Catheter Ablation System towards commercialization. Her extensive background in cardiovascular and electrophysiology therapies, coupled with a track record of building and scaling medtech businesses, is highly relevant to the company's strategic priorities. The substantial performance-based equity awards, tied to ambitious market capitalization and revenue milestones, align executive incentives with significant future growth, signaling confidence in the company's long-term potential. This move follows recent positive news regarding the enrollment of the first patients in its pivotal NANOPULSE-AF clinical study, indicating a strategic build-up of leadership for upcoming commercial phases.